Effects of erythropoiesis-stimulating agents on heart failure patients with anemia: a meta-analysis

doi:10.5114/aic.2016.61647

CORC > 兰州大学 > 兰州大学 > 第一临床医学院 > 期刊论文

	Effects of erythropoiesis-stimulating agents on heart failure patients with anemia: a meta-analysis
	Zhang, HL; Zhang, P; Zhang, YH; Yani, JQ; Dongi, PS; Wang, YY; Niue, XW; Zhang, HL (reprint author), Henan Univ Sci & Technol, Affiliated Hosp 1, Dept Cardiol, Jinghua St, Luoyang 471000, Peoples R China.
刊名	POSTEPY W KARDIOLOGII INTERWENCYJNEJ
	2016-09
卷号	12 期号:3 页码:247-253
关键词	meta-analysis heart failure randomized controlled trials anemia erythropoietin-stimulating agents
ISSN号	1734-9338
DOI	10.5114/aic.2016.61647
文献子类	Article
英文摘要	Introduction: Heart failure (HF) is always complicated with anemia and is associated with bad prognosis in this patient population. Several studies have assessed the potential role of erythropoietin-stimulating agent (ESA) in improving cardiac function and reducing the number of hospitalizations in anemic patients with HF. Aim: We performed a meta-analysis to assess the potential role of ESA in the treatment of anemic patients with HF. Material and methods: A literature and Medline search was performed to identify studies with control groups that examined the efficacy of ESA therapy in patients with HF and anemia. Results: A total of 11 studies were included (n = 3044 subjects) in the final analysis. Compared to placebo, ESA therapy was associated with increased hemoglobin levels (1.89 g/dl; 95% CI: 1.64-2.14, p < 0.00001), increased left ventricular ejection fraction (LVEF) to 6.88 (95% CI: 0.49-13.28, p = 0.03), decreased B-type natriuretic protein (-272.20; 95% CI: (-444.52)-(-99.89), p = 0.002), improvement in New York Heart Association functional class to -0.33 mean difference (95% CI: (-0.44)-(-0.23), p < 0.00001), and decreased hospitalization (OR = 0.61, 95% CI: 0.39-0.94, p = 0.02). There was no significant between-group difference in all-cause mortality (OR = 0.78, 95% CI: 0.51-1.21, p = 0.27). Conclusions: The treatment of anemia with ESA therapy did not reduce the rate of all-cause mortality among patients with heart failure, but ESA therapy made a potential important contribution to patients' symptomatic improvement.
学科主题	Cardiovascular System & Cardiology
出版地	POZNAN
语种	英语
WOS记录号	WOS:000382411600009
内容类型	期刊论文
源URL	[http://ir.lzu.edu.cn/handle/262010/178668]
专题	第一临床医学院_期刊论文
通讯作者	Zhang, HL (reprint author), Henan Univ Sci & Technol, Affiliated Hosp 1, Dept Cardiol, Jinghua St, Luoyang 471000, Peoples R China.
推荐引用方式 GB/T 7714	Zhang, HL,Zhang, P,Zhang, YH,et al. Effects of erythropoiesis-stimulating agents on heart failure patients with anemia: a meta-analysis[J]. POSTEPY W KARDIOLOGII INTERWENCYJNEJ,2016,12(3):247-253.
APA	Zhang, HL.,Zhang, P.,Zhang, YH.,Yani, JQ.,Dongi, PS.,...&Zhang, HL .(2016).Effects of erythropoiesis-stimulating agents on heart failure patients with anemia: a meta-analysis.POSTEPY W KARDIOLOGII INTERWENCYJNEJ,12(3),247-253.
MLA	Zhang, HL,et al."Effects of erythropoiesis-stimulating agents on heart failure patients with anemia: a meta-analysis".POSTEPY W KARDIOLOGII INTERWENCYJNEJ 12.3(2016):247-253.